Expert Opin Biol Ther. 2026 Jun 28. doi: 10.1080/14712598.2026.2694688. Online ahead of print.
ABSTRACT
OBJECTIVES: To assess prescription patterns and describe the long-term real-life effectiveness of different TNF inhibitors (TNFi) in juvenile idiopathic arthritis related uveitis (JIA-U).
METHODS: Patients with JIA-U treated with TNFi were retrospectively enrolled.
RESULTS: 96 JIA-U patients (77% female) with an age at diagnosis of 2.44 [interquartile range (IQR) 1.56-3.81] and a median follow-up of 19 years were included. Adalimumab was the most frequently prescribed TNFi (61%), followed by etanercept (19%), infliximab (15%) and golimumab (5%). Overall, adalimumab showed the lowest complications rate (51%; p < 0.001) and median number of uveitis relapse (1; IQR 0-2; p = 0.012). Conversely etanercept showed the highest median number of uveitis relapses (4; IQR 1-5). The cumulative incidences curves for ‘uveitis relapse’ were similar among TNFi. Conversely, when ‘treatment change’ was considered as the event, a significantly higher risk for patients treated with infliximab compared with those receiving adalimumab emerged (HR 3.06, 95% CI 1.41-6.63; p < 0.01).
CONCLUSIONS: All TNFi appear to be effective for long-term management of JIA-U. We observed some differences in number of uveitis relapses and ocular complication rates favoring adalimumab over infliximab and etanercept, findings to be further confirmed in prospective studies.
PMID:42365450 | DOI:10.1080/14712598.2026.2694688
